However, about 15–20% of breast cancer patients are diagnosed with triple-negative breast cancer (TNBC), which is characterized by estrogen receptor (ER-) negative, progesterone receptor (PR-) negative, and human epidermal growth factor receptor 2 (HER2-) negative [3]. Here, ESR1 is linked to triple-negative breast carcinoma.